Pacira Pharmaceuticals Inc. (PCRX)

33.75
NASDAQ : Health Technology
Prev Close 34.25
Day Low/High 32.91 / 34.35
52 Wk Low/High 26.95 / 51.10
Avg Volume 874.10K
Exchange NASDAQ
Shares Outstanding 40.73M
Market Cap 1.40B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Strong On High Volume: Pacira Pharmaceuticals (PCRX)

Strong On High Volume: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a strong on high relative volume candidate

New Survey Sheds Light On Prescription Drug Use Among Women After Surgery In The United States

New Survey Sheds Light On Prescription Drug Use Among Women After Surgery In The United States

Pacira and HealthyWomen Launch 'Voice Your Choice' Campaign Urging Patients to Know and Discuss Their Pain Control Options Before Surgery

New Study Finds Decreased Opioid Use, Hospital Stay And Readmission Rates With EXPAREL Following Knee Replacement Surgery

New Study Finds Decreased Opioid Use, Hospital Stay And Readmission Rates With EXPAREL Following Knee Replacement Surgery

Data Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

5 Lesser-Known Stocks Goldman Sachs Recommends You Trust

5 Lesser-Known Stocks Goldman Sachs Recommends You Trust

These companies aren't household names, but they're on track for market-beating performance.

Goldman Sachs Picks 8 Small-Cap Stocks Poised to Double Earnings in 3 Years

Goldman Sachs Picks 8 Small-Cap Stocks Poised to Double Earnings in 3 Years

The recent pullback has created opportunity to buy small-cap stocks, particularly those with strong growth prospects over the next few years. Here's Goldman's picks.

Pacira Pharmaceuticals (PCRX) Strong On High Relative Volume Today

Pacira Pharmaceuticals (PCRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a strong on high relative volume candidate

Pacira Pharmaceuticals is Now Oversold

Pacira Pharmaceuticals is Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Pacira Pharmaceuticals (PCRX) Is Weak On High Volume Today

Pacira Pharmaceuticals (PCRX) Is Weak On High Volume Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Insider Trading Alert - MRD, RNR And PCRX Traded By Insiders

Insider Trading Alert - MRD, RNR And PCRX Traded By Insiders

Stocks with insider trader activity include MRD, RNR and PCRX

Pacira Pharmaceuticals Seeks Court Injunction To Defend Its Rights To Share Information About EXPAREL® Consistent With Its FDA-Approved Indication

Pacira Pharmaceuticals Seeks Court Injunction To Defend Its Rights To Share Information About EXPAREL® Consistent With Its FDA-Approved Indication

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today filed a lawsuit against the U.

Pacira Pharmaceuticals (PCRX) Weak On High Volume

Pacira Pharmaceuticals (PCRX) Weak On High Volume

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, As Senior Vice President And Chief Medical Officer

Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, As Senior Vice President And Chief Medical Officer

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of James B.

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

These stocks have had a really good run, says Wedbush Securities, which is holding its annual health care investment conference in New York.

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.

Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China

Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide From China

China's problems continue to knock a number of U.S. stocks upside the head, Cramer says.

Perilous Reversal Stock: Pacira Pharmaceuticals (PCRX)

Perilous Reversal Stock: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Pacira Pharmaceuticals, Inc. To Present At Investor Conferences In August

Pacira Pharmaceuticals, Inc. To Present At Investor Conferences In August

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the...

Watch Out: Barbarians At The Gate For Pacira Pharmaceuticals (PCRX)

Watch Out: Barbarians At The Gate For Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results

Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results...

Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results For Controlling Postsurgical Pain In Dogs

Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results For Controlling Postsurgical Pain In Dogs

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc.

Pacira Pharmaceuticals Announces Timing For Second Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For Second Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015.

Pacira Pharmaceuticals Appoints Scott Braunstein, MD, To Oversee Strategy And Corporate Development

Pacira Pharmaceuticals Appoints Scott Braunstein, MD, To Oversee Strategy And Corporate Development

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development.

PCRX: Insiders vs. Shorts

PCRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 05/15/2015 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 6.77 "days to cover" versus the median component at 5.60.

TheStreet Quant Rating: D (Sell)